Kevin Conway
About Kevin Conway
Kevin Conway is Generation Bio’s Chief Financial Officer and Treasurer, appointed in January 2025; he is 38, a CPA in Massachusetts, with a B.S. in communications (Ithaca College) and an M.S. in accounting (University of Massachusetts, Boston) . His compensation is governed by the company’s executive pay framework (talent committee oversight, market benchmarking to the 50th percentile peer group) and annual incentives tied to corporate performance goals, which were assessed at 100% achievement for 2024 . The company prohibits hedging and pledging of its securities and has a Dodd-Frank compliant clawback policy adopted October 2, 2023 .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Generation Bio | Assistant Corporate Controller | Jul 2019–Apr 2020 | Accounting leadership and controls |
| Generation Bio | Corporate Controller | Apr 2020–Apr 2021 | Financial reporting and control environment |
| Generation Bio | Senior Director, Corporate Controller | Apr 2021–Mar 2022 | Scaling finance operations |
| Generation Bio | Vice President, Finance | Mar 2022–Jan 2025 | Finance leadership, planning, treasury |
| Generation Bio | Chief Financial Officer & Treasurer | Jan 2025–present | CFO oversight of finance, capital allocation |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Solid Biosciences Inc. | Assistant Controller | Aug 2018–Jul 2019 | External reporting and controls at a life sciences issuer |
Fixed Compensation
- Executive pay is set and overseen by the Talent Committee, targeting the 50th percentile of a biotechnology peer group for base, short-term and long-term incentives, informed by Compensia and Aon data; individual executive base salary and target bonus for Kevin Conway are not disclosed in the proxy .
Performance Compensation
| Metric (2024 Corporate Goals) | Target | Actual | Weighting | Payout Factor |
|---|---|---|---|---|
| Demonstrate T cell ctLNP delivery (mRNA GFP) in non-human primates | Preclinical proof-of-delivery | Achieved | Not disclosed | Included in 100% corporate achievement |
| Demonstrate selective CAR expression via T cell-selective ctLNP in mice | Preclinical pharmacodynamics | Achieved | Not disclosed | Included in 100% corporate achievement |
| Identify alternative polymers to enable redosing | Platform advancement | Achieved | Not disclosed | Included in 100% corporate achievement |
| Update employee development programs | Talent/engagement | Achieved | Not disclosed | Included in 100% corporate achievement |
| Develop preclinical siRNA ctLNP proof-of-concept and investor thesis | Translational readiness | Achieved | Not disclosed | Included in 100% corporate achievement |
- Company-wide annual incentive factor for 2024 was determined at 100% of target by the board .
Equity Ownership & Alignment
| Policy/Practice | Detail |
|---|---|
| Anti-hedging and anti-pledging | Insider Trading Policy prohibits short sales, derivatives, hedging, purchasing on margin, and pledging company stock . |
| Clawback | Clawback policy effective Oct 2, 2023 for incentive compensation over prior three fiscal years upon a financial restatement per Dodd-Frank/Nasdaq . |
| Ownership guidelines | Company states it does not have formal executive stock ownership guidelines . |
| Standard option terms | 10-year term; time-based vesting over 4 years (25% at first anniversary, then equal quarterly installments) . |
| Standard RSU terms | 4-year vesting (25% at first anniversary/15th day of the month, then equal quarterly installments) . |
Insider filings for Kevin Conway in 2025:
| Filing Date | Form | Document Date | Source |
|---|---|---|---|
| Jan 14, 2025 | Form 4 | Jan 10, 2025 | |
| Jan 17, 2025 | Form 4 | Jan 15, 2025 | |
| Apr 17, 2025 | Form 4 | Apr 15, 2025 | |
| Jul 17, 2025 | Form 4 | Jul 15, 2025 | |
| Oct 17, 2025 | Form 4 | Oct 15, 2025 | |
| Initial statement | Form 3 | Noted (Conway Kevin John) |
- Exact beneficial ownership totals (shares/derivatives), vest schedules, and any sales disclosed in these forms should be reviewed directly in each filing; the proxy’s beneficial ownership table covers directors and 2024 NEOs and does not list Kevin Conway .
Employment Terms
| Item | Terms |
|---|---|
| Role start date | Appointed Chief Financial Officer and Treasurer in January 2025 . |
| Delegated equity grant authority | Talent Committee delegated authority under the 2020 Stock Incentive Plan to the CEO and CFO to approve option/RSU grants for non-leadership hires/promotions (within preset limits) . |
| Non-compete & non-solicit | Standard agreements require no competition and no solicitation during employment and for one year post-termination; confidentiality and IP assignment obligations apply . |
| Severance (no change-in-control) – other executive officers (includes CFO) | 9 months base salary continuation; up to 9 months COBRA premiums; discretionary prorated annual cash incentive; 25% acceleration of unvested equity . |
| Severance (within 12 months post change-in-control) – other executive officers (includes CFO) | Lump sum equal to 12 months base; up to 12 months COBRA premiums; lump sum equal to 100% of target annual incentive; full acceleration of all outstanding unvested equity . |
Investment Implications
- Alignment and controls: Anti-hedging/pledging policy and clawback strengthen alignment and reduce governance risk; absence of formal ownership guidelines limits enforced “skin in the game” but is explicitly disclosed .
- Retention economics: CFO-level severance provides meaningful cash continuity and equity acceleration, particularly under change-of-control, which can lower voluntary departure risk pre-close but may increase turnover risk post-close given full acceleration .
- Equity flow and potential supply: Standard four-year, quarterly vesting for options/RSUs coupled with multiple 2025 Form 4 filings indicates ongoing equity activity; monitor filings for tax-withholding sales or net exercises as potential periodic supply signals .
- Execution context: The company’s 2024 corporate objectives were met at 100%, supporting pay-for-performance credibility; in Q3 2025, cash, cash equivalents, and marketable securities were $89.6 million (vs. $185.2 million at year-end 2024), highlighting runway management as a key CFO lever amid evolving R&D priorities .